Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Sell
48
AXGN Quote, Financials, Valuation and Earnings
Last price:
$16.59
Seasonality move
:
12.1%
Day range:
$16.39 - $16.69
52-week range:
$5.65 - $21.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.88x
P/B ratio:
7.00x
Volume:
402.2K
Avg. volume:
480.3K
1-year change:
189.42%
Market cap:
$727.7M
Revenue:
$187.3M
EPS (TTM):
-$0.22
Analysts' Opinion
-
Consensus RatingAxogen has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $25.71, Axogen has an estimated upside of 56.7% from its current price of $16.41.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $24.00 representing 100% downside risk from its current price of $16.41.
Fair Value
-
According to the consensus of 5 analysts, Axogen has 56.7% upside to fair value with a price target of $25.71 per share.
AXGN vs. S&P 500
-
Over the past 5 trading days, Axogen has underperformed the S&P 500 by -0.66% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Axogen does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Axogen has grown year-over-year revenues for 11 quarters straight. In the most recent quarter Axogen reported revenues of $49.4M.
Earnings Growth
-
Axogen earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Axogen reported earnings per share of $0.01.
Enterprise value:
741.7M
EV / Invested capital:
--
Price / LTM sales:
3.88x
EV / EBIT:
--
EV / Revenue:
3.96x
PEG ratio (5yr expected):
--
EV / Free cash flow:
67,426.89x
Price / Operating cash flow:
66,023.45x
Enterprise value / EBITDA:
122.03x
Gross Profit (TTM):
$142M
Return On Assets:
-5.15%
Net Income Margin (TTM):
-5.32%
Return On Equity:
-10.21%
Return On Invested Capital:
-6.89%
Operating Margin:
4.08%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $138.6M | $159M | $187.3M | $42.9M | $49.4M | |
| Gross Profit | $108.8M | $121.9M | $142M | $32M | $37.6M | |
| Operating Income | -$29.7M | -$21.5M | -$3.3M | -$3.2M | $2M | |
| EBITDA | -$23.5M | -$13.3M | $6.1M | -$197K | $4.2M | |
| Diluted EPS | -$0.68 | -$0.52 | -$0.22 | -$0.09 | $0.01 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $145.3M | $127M | $98.1M | $88M | $99.2M | |
| Total Assets | $201.4M | $208M | $195.4M | $196.8M | $203.7M | |
| Current Liabilities | $22.8M | $24.3M | $23.8M | $30.4M | $30.6M | |
| Total Liabilities | $78.2M | $95.5M | $94.4M | $101.2M | $99.8M | |
| Total Equity | $123.1M | $112.6M | $101M | $95.7M | $103.9M | |
| Total Debt | $32M | $44.8M | $45.7M | $46.6M | $47.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.1M | -$5.7M | $4.5M | -$211K | $8.7M | |
| Cash From Investing | -$3.2M | $19.3M | -$10.3M | -$277K | -$813K | |
| Cash From Financing | $1.8M | $2M | $2.3M | $418K | $970K | |
| Free Cash Flow | -$37.3M | -$20.6M | $11K | -$2M | $7.9M | |
AXGN
Sector
Market Cap
$727.7M
$34.5M
Price % of 52-Week High
78.14%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.79%
1-Year Price Total Return
189.42%
-42.08%
Beta (5-Year)
1.195
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$16.52
200-day SMA
Buy
Level
$14.88
Bollinger Bands (100)
Sell
Level
15.72 - 18.6
Chaikin Money Flow
Buy
Level
24.1M
20-day SMA
Buy
Level
$16.09
Relative Strength Index (RSI14)
Sell
Level
48.21
ADX Line
Sell
Level
17.8
Williams %R
Neutral
Level
-34.5528
50-day SMA
Sell
Level
$17.33
MACD (12, 26)
Sell
Level
-0.16
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
42.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.6669)
Buy
CA Score
(Annual)
Level (-0.1454)
Buy
Beneish M-Score
(Annual)
Level (-2.748)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (1.5635)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Stock Forecast FAQ
In the current month, AXGN has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AXGN average analyst price target in the past 3 months is $25.71.
-
Where Will Axogen Stock Be In 1 Year?
According to analysts, the consensus estimate is that Axogen share price will rise to $25.71 per share over the next 12 months.
-
What Do Analysts Say About Axogen?
Analysts are divided on their view about Axogen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Axogen is a Sell and believe this share price will drop from its current level to $24.00.
-
What Is Axogen's Price Target?
The price target for Axogen over the next 1-year time period is forecast to be $25.71 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AXGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Axogen is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AXGN?
You can purchase shares of Axogen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Axogen shares.
-
What Is The Axogen Share Price Today?
Axogen was last trading at $16.59 per share. This represents the most recent stock quote for Axogen. Yesterday, Axogen closed at $16.41 per share.
-
How To Buy Axogen Stock Online?
In order to purchase Axogen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 7
Regencell Bioscience Holdings [RGC] is up 15.89% over the past day.
Buy
77
FARO alert for May 7
Faro Technologies [FARO] is down 0.14% over the past day.
Buy
53
SRPT alert for May 7
Sarepta Therapeutics [SRPT] is down 20.47% over the past day.
